NCT03866603: ROPAD

Rostock International Parkinson's Disease Study (ROPAD)

Completed Last updated 13 April 2026

What this trial tests

trial in Parkinson´s Disease in 20,112 participants. Completed in 10 October 2024.

Timeline

30 May 2019

Primary endpoint
10 October 2024

10 October 2024

Quick facts

Lead sponsor	CENTOGENE GmbH Rostock
Status	Completed
Study type	OBSERVATIONAL
Enrollment	20,112
Start date	30 May 2019
Primary completion	10 October 2024
Estimated completion	10 October 2024
Sites	110 locations across France, Italy, Greece, Belgium, United Kingdom, Germany, Israel, Norway

Conditions studied

• Parkinson´s Disease — all drugs for Parkinson´s Disease →

Sponsor

CENTOGENE GmbH Rostock

Who can join

Adults 30 to 80, any sex, with Parkinson´s Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Rostock International Parkinson's Disease Study - An International, multicenter, epidemiological observational study aiming at identification of LRRK2-positive patients, the recruitment of 25,000 PD participants and the establishment of a candidate biomarker in the LRRK2-positive cohort.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. The Rostock International Parkinson's Disease (ROPAD) Study: Protocol and Initial Findings.
   Skrahina V, Gaber H, Vollstedt EJ, Förster TM, et al · · 2021 · cited 87× · PMID 33314351 · DOI 10.1002/mds.28416
2. Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson's disease study.
   Westenberger A, Skrahina V, Usnich T, Beetz C, et al · · 2024 · cited 81× · PMID 39087914 · DOI 10.1093/brain/awae188
3. Therapy of Parkinson's Disease Subtypes.
   Marras C, Chaudhuri KR, Titova N, Mestre TA. · · 2020 · cited 60× · PMID 32749651 · DOI 10.1007/s13311-020-00894-7
4. Planning for Prevention of Parkinson Disease: Now Is the Time.
   Crotty GF, Keavney JL, Alcalay RN, Marek K, et al · · 2022 · cited 22× · PMID 36219787 · DOI 10.1212/wnl.0000000000200789
5. Genetic Testing in Parkinson's Disease.
   Pal G, Cook L, Schulze J, Verbrugge J, et al · · 2023 · cited 21× · PMID 37365908 · DOI 10.1002/mds.29500
6. Consensus Guidance for Genetic Counseling in GBA1 Variants: A Focus on Parkinson's Disease.
   Vieira SRL, Mezabrovschi R, Toffoli M, Del Pozo SL, et al · · 2024 · cited 16× · PMID 39258449 · DOI 10.1002/mds.30006
7. Deep brain stimulation in Early Onset Parkinson's disease.
   Krause P, Reimer J, Kaplan J, Borngräber F, et al · · 2022 · cited 15× · PMID 36468049 · DOI 10.3389/fneur.2022.1041449
8. Change in movement disorder specialist attitudes to genetic testing after implementation of PD GENEration.
   Wang J, Ibrahim V, Agin-Liebes J, Nance M, et al · · 2026 · PMID 41953728 · DOI 10.1016/j.gimo.2026.104391